Skip to main content
2024 Guide to Patient Support Services


2024 PSS Guide

Sandoz One Source Support Services

Novartis Patient Assistance Foundation

Sandoz, a Novartis Division, offers the Sandoz One Source patient support program to assist patients while taking Zarxio or Ziextenzo (Table).

Sandoz One Source

This program offers several supportive resources for patients taking Zarxio or Ziextenzo, including a Commercial Co-Pay Program, in-home injection training, a Product Replacement Program, and a Patient Assistance Program.

Commercial Co-Pay Program

Eligible patients with commercial insurance may pay as little as $0 for Zarxio or Ziextenzo.

Product Replacement Program

Sandoz One Source offers a simple product replacement process for spoiled Zarxio or Ziextenzo under the following circumstances:

  • Product was mishandled, dropped, or broken
  • There was an admixture error
  • Product was inappropriately stored or refrigerated, or was frozen
  • Product was reconstituted but not administered due to an unforeseen reason.

Contact Sandoz One Source at 844-726-3691 to request a replacement product.

Novartis Patient Assistance Foundation

The Novartis Patient Assistance Foundation (NPAF) provides assistance to uninsured and underinsured patients who have been prescribed Zarxio or Ziextenzo. To learn more, call 800-277-2254 or visit NPAF.

To learn more, or to enroll your patient in the Sandoz One Source program, call 844-726-3691 or visit Zarxio or Ziextenzo.

TABLE Sandoz Oncology Supportive Care Drugs

Patient support programs

Zarxio (filgrastim-sndz)
Patient support programs

Ziextenzo (pegfilgrastim-bmez)
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies who are receiving myelo­suppressive anticancer drugs with a significant incidence of febrile neutropenia
Patient support programs

Zarxio (filgrastim-sndz) Indications

To decrease the incidence of febrile neutropenia in patients with nonmyeloid malignancies using myelo­suppressive anticancer drugs; reduce time to neutrophil recovery and duration of fever after induction or consolidation chemotherapy in patients with acute myeloid leukemia; reduce the duration of neutropenia and neutropenia-related sequelae in patients with nonmyeloid malignancies receiving myeloablative chemotherapy followed by bone marrow transplantation; mobilize autologous hematopoietic progenitor cells; reduce the incidence and duration of sequelae of neutropenia in symptomatic patients with congenital‚ cyclic‚ or idiopathic neutropenia